首页> 外文OA文献 >PDB73 Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective

【2h】

PDB73 Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective

机译：通过使用新型抗糖尿病药，Dapagliflozin（Forxiga®）和艾塞那肽（Bydureon®）作为二甲双胍的附加药物，延迟胰岛素治疗的PDB73经济评估；英国Nhs视角的成本效益分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Charokopou M.; Vioix H.; Verheggen B.G.; Maddocks D.; Bratt T.; Franks D.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective [J] . M. Charokopou, P. McEwan, S. Lister, BMC Health Services Research . 2015,第1期

机译：从英国医疗保健系统的角度来看，达格列净与DPP-4抑制剂作为二甲双胍的附加药物在治疗2型糖尿病中的成本效益
2. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China [J] . Gu Shuyan, Wang Xiaoyong, Qiao Qing, Diabetes, obesity & metabolism . 2017,第12期

机译：Exenatide的成本效益每日两次与胰岛素狼獾作为中国2型糖尿病患者口服抗糖尿病药物的添加疗法
3. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece [J] . Tzanetakos Charalampos, Tentolouris Nicholas, Kourlaba Georgia, Clinical drug investigation . 2016,第8期

机译：Dapagliflozin作为二甲双胍治疗希腊2型糖尿病的附加药物的成本效益
4. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective [O] . M. Charokopou, P. McEwan, S. Lister, 2015

机译：从英国医疗保健系统的角度来看达格列净与DPP-4抑制剂作为二甲双胍的附加药物在治疗2型糖尿病中的成本效益
5. PDB67 Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective [O] . Charokopou M., Vioix H., Verheggen B.G., 2014

机译：PDB67达格列净（Forxiga®）与格列吡嗪作为2型糖尿病（T2dm）的附加治疗方法；英国Nhs观点基于长期临床证据的成本-效果更新

PDB73 Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective

著录项

引文网络

相似文献

相关主题

期刊订阅